Bold Therapeutics was founded in 2018 by a team of biopharma industry veterans to develop and commercialize BOLD-100, a first-in-class anti-resistance therapeutic.

BOLD-100, a ruthenium-based small molecule therapeutic, appears to significantly enhance the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival and proliferation pathway.

Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.

Our Team

Profile Photo

E. Russell McAllister
Chief Executive Officer

  • More than 20 years of biopharma industry experience, focusing on corporate strategy and business development
  • Current CEO, Intezyne (Oncology); Former CFO, Intezyne (Oncology); Qu Biologics (Immuno-oncology) and Lakewood-Amedex (Infectious disease)
  • 2018 CFO of the Year Honoree, Tampa Bay Business Journal (TBBJ)
  • 2017 ‘Deal of the Year’ recipient; Southeast Bio (SEBIO)
  • Former Managing Director, Head of Healthcare Strategic Advisory, H.C. Wainwright / Rodman & Renshaw
  • 5-Star-Rated Senior Equity Research Analyst (Biopharmaceuticals), Merriman Curhan Ford & Co. and Thomas Weisel Partners (Stifel)
  • PhD candidate, Behavioral Finance, University of Illinois; MS Accounting / MBA, Northeastern University
Profile Photo

Jim Pankovich
Executive Vice President, Clinical Development

  • More than 25 years of biopharma industry experience, focusing on clinical study strategy and management.
  • Former VP, Clinical Operations and Drug Development, Qu Biologics (Immuno-oncology); CSO, CIHR Canadian HIV Trial Network (Infectious disease); Sr Director, Clinical Research, Migenix (Infectious disease); Assc Director, Clinical Research, Inex Pharmaceuticals (Oncology)
  • MS, Experimental Medicine, University of Alberta
  • MBA, Queen’s University
Profile Photo

Michelle Jones
Director, Clinical Development

  • More than 15 years of biopharma industry experience, focusing on clinical trial management and operations.
  • Former Associate Director, Clinical Operations, Qu Biologics (Immuno-oncology); Clinical Operations Manager, Symvivo (Immuno-oncology); Research Manager, CIHR Canadian HIV Trial Network (Infectious disease); Clinical & Regulatory Affairs Manager, Protiva Biotherapeutics (Oncology & Infectious disease)
  • MSc, Nursing, McGill University
  • MBA (Management of Biotechnology Specialization), Simon Fraser University
Profile Photo

Mark Bazett, PhD
Director, Preclinical Development

  • 5 years of biopharma industry experience, focusing on preclinical development.
  • Former Preclinical Immunotherapy Lead, Novelogics (Oncology); Director of Preclinical and Translational Research, Qu Biologics (Immuno-oncology)
  • PhD, Immunology, McGill University
Profile Photo

Adam Carie, PhD
Director of CMC & Nonclinical Development

  • More than 10 years biopharma industry experience developing novel oncology therapeutics, including IVECTTM™ polymer nanoparticle technology from concept to clinic.
  • More than 10 years of biopharma industry experience, focusing on oncology product development, formulation, optimization, logistics and manufacturing.
  • Focus on nonclinical development, manufacturing, quality systems, supply chain management, logistics, and regulatory support.
  • Current Director of Product Development for Intezyne, also managed CMC for BOLD-100 during development at Intezyne.
  • PhD in Cancer Biology from University of South Florida. PhD research in Cancer Drug Discovery at H. Lee Moffitt Cancer Center in Tampa, FL.
Profile Photo
Melissa Smith
Office Manager
  • BA, Criminology (Concentrations: Psychology and Sociology), University of the Fraser Valley
  • AA, Kinesiology (Concentrations: Anatomy and Physiology), Langara College
  • Responsible for office management, conference and travel logistics, and providing support for accounting, business development, finance and investor relations.
Profile Photo
Carly Hastings
Operations Associate
  • BS, Health Sciences (Concentrations: Health Management and Biological Sciences), University of South Florida
  • Responsible for accounting, clinical trial logistics and procurement, as well as providing support for business development, finance and investor relations.
Profile Photo
Elizabeth Daley
Executive Assistant
  • BS, Cell and Molecular Biology, University of South Florida (May 2020).
  • BS, Health Sciences (Concentration: Health Management), University of South Florida (May 2020).
  • Experience in managing administrative duties, assisting with project management, accounting, and investor relations.
  • Responsible for competitive intelligence and providing support for accounting, business development, and investor relations.
Board Of Directors

Board Of Directors

Glenn Walthall
Chairman
Russ McAllister
CEO
Jim Pankovich
EVP Clinical Development
Simon Sutcliffe
Director
Hooshmand Sheshbaradaran
Director
Careers

Careers

Bold Therapeutics hires great people who are passionate about clinical development and want to make an impact in the lives of cancer patients. Although Bold is not currently hiring for specific positions, we encourage exceptional candidates to contact us at [email protected]